



29 Taras Avenue,
Altona North, Vic 3025
Australia.

PO Box 62
Sunshine, Vic 3020
Australia.

Telephone: +61 3 9243 3311
Facsimile: +61 3 9243 3300
Email: gudhold@gud.com.au
Internet: www.gud.com.au

25 July, 2014

Manager, Company Announcements
ASX Limited
Level 4, 20 Bridge Street
Sydney NSW 2000

Dear Sir

**Full Year Ended 30 June, 2014
Results Briefing**

Attached is a copy of the Full Year ended 30 June, 2014 Results Briefing to analysts and brokers, presented by Jonathan Ling, Managing Director, GUD Holdings Limited.

Yours faithfully

A handwritten signature in black ink, appearing to read 'Malcolm G Tyler', with a long horizontal flourish extending to the right.

Malcolm G Tyler
Company Secretary

Att:

FY14 results

Year ended 30 June **2014**



Jonathan Ling
Managing Director

Result key points

- ▶ Full year NPAT of \$17.7 million
 - includes \$13.3 million after tax of restructuring and impairment costs
- ▶ Underlying EBIT of \$49.0 million down 13% on pcg
 - Improvements in second half performance driven by turnaround in Dexion
 - Underlying H2 EBIT of \$25.1 million up on first half and pcg
- ▶ Restructuring and impairment costs of \$19.0 million pre-tax fully provided
 - \$16.1 million in Dexion-related activities, to be completed in H1 FY15
 - Financial benefits to become evident in FY15
- ▶ Final dividend of 18 cents per share fully franked
 - Total dividends of 36 cents
 - Payout ratio of 83% on underlying EPS

Note: All underlying measures noted in this document are non-IFRS and have not been subject to audit or review



Financial summary

\$ million	FY13	FY14	% Change
Revenue	596.5	591.6	-1%
Underlying EBITDA	70.5	63.4	-10%
Depreciation	(7.7)	(7.9)	
Amortisation	(6.4)	(6.4)	
Underlying EBIT	56.4	49.0	-13%
Net Finance Expense	(5.2)	(6.4)	
Underlying Profit before Tax	51.2	42.7	
Tax	(13.8)	(11.7)	
Underlying NPAT	37.4	31.0	-17%
Restructuring Costs after Tax	(5.9)	(13.3)	
Reported NPAT	31.5	17.7	-44%
EPS & Dividend - cents			
Underlying EPS	52.5	43.5	-17%
Reported EPS	44.2	24.8	-44%
Total Dividend	52.0	36.0	-31%
Special Dividend	20.0		

Revenue and EBIT growth in Oates, Automotive, Davey and Lock Focus offset by declines in Sunbeam and Dexion

Financial position

- ▶ Debt facility renewed
 - Total facility reduced to \$150 million from \$180 million
 - Lower borrowing and facility costs achieved
 - Maturity tranches of two and four years
- ▶ Net debt of \$98.4 million at 30 June 2014
 - Net debt to equity comfortable at 47%
 - Substantial headroom on new facility
- ▶ Healthy interest cover of 8.7 times (underlying EBITA/net interest)
- ▶ 401,827 shares acquired through on-market buy back
- ▶ Total dividends of 36 cents per share fully franked for the full year
 - Final dividend of 18 cents per share payable 3 September 2014



Restructuring projects - pre-tax costs and benefits

Project	Status	Cost	Annualised Benefit
Dexion - Kings Park closure	Completion Q1 FY15	\$11.8 m	\$6.5 m
Dexion- Elite Built exit	Completed	\$2.8 m	\$1.0 m
Dexion - Commercial manufacturing closure	Completion Q2 FY15	\$1.5 m	\$0.5 m
Sunbeam - overhead reductions	Completed	\$0.7 m	\$0.9 m
Sunbeam - product development write-offs	Completed	\$1.5 m	-
Davey - overhead reductions	Completed	\$0.2 m	\$0.6 m
Oates - overhead reductions	Completed	\$0.3 m	\$0.5 m
Automotive - overhead reductions	Completed	\$0.3 m	\$0.0 m
TOTALS		\$19.0 m	\$10.0 m

Group-wide performance improvement initiatives


- ▶ Detailed profitability analyses completed in Dexion, Sunbeam, Davey and Oates:
 - Profit improvement opportunities identified and being progressively captured
 - Focus on supply chain, warranty, cost-to-serve and product rationalisation
 - Up to \$20 million of annualised benefit to contribute over next two to three years

- ▶ Innovation initiative commenced late 2013
 - First breakthrough ideas generated and feasibility studies occurring
 - Initial release of products and services anticipated for early FY16
 - New distribution channels being pursued currently

- ▶ Implementation of high performance culture
 - New CEO appointments at Dexion, Sunbeam and Davey over FY14
 - Increased accountability for delivery of business objectives


GUD business mix

FY14 revenue - \$592m



Dexion 34% and Sunbeam 20% of revenue

FY14 underlying operational EBIT*



Dexion and Sunbeam currently contribute only 9% of underlying operational EBIT, highlighting a substantial EBIT growth opportunity

*Underlying EBIT before Unallocated Costs

Business summary



Revenue down 2% to \$200m
Underlying EBIT down 51% to \$3.1m



Revenue down 9% to \$117m
Underlying EBIT down 83% to \$1.5m



Revenue up 1% to \$102m
Underlying EBIT up 6% to \$8.8m



Revenue up 9% to \$95m
Underlying EBIT up 8% to \$30.3m



Revenue up 2% to \$67m
Underlying EBIT up 3% to \$11.1 m



Revenue up 6% to \$11m
Underlying EBIT up 4% to \$0.9 m



Dexion

\$ million	FY13	FY14	% Change
Sales	204.0	199.5	-2%
EBITDA	10.0	6.9	-31%
Depreciation	1.8	1.8	0%
Amortisation	1.9	2.0	5%
Underlying EBIT	6.3	3.1	-51%
<i>EBIT/Sales %</i>	<i>3%</i>	<i>2%</i>	



- ▶ FY14 disappointing but stronger results produced in second half
- ▶ Higher project revenue in Australia and New Zealand contributed to H2
- ▶ Dexion order book up by 55% on end-FY13 level to \$69 million
- ▶ New Jumbo roll forming plant installed in Malaysia
- ▶ Primary focus has been on restructuring projects and profit improvement plan to deliver substantial benefits in FY15

Sunbeam


\$ million	FY13	FY14	% Change
Sales	128.6	117.2	-9%
EBITDA	15.7	8.4	-47%
Depreciation	2.4	2.6	10%
Amortisation	4.2	4.2	0%
Underlying EBIT	9.1	1.5	-83%
<i>EBIT/Sales %</i>	<i>7%</i>	<i>1%</i>	



- ▶ Sales declined due to prevailing competitive market conditions and a lack of innovative new products
- ▶ Margins declined due to competition stifling opportunities for price increases to offset lower dollar effect
- ▶ New CEO commenced December 2013 and management team refreshed
- ▶ Profit improvement plan developed with a focus on cost-to-serve, supply chain, warranty, product rationalisation and trading terms
- ▶ Innovation hub formed to drive ideation and development of new products

Davey

\$ million	FY13	FY14	% Change
Sales	100.9	102.1	1%
EBITDA	10.1	10.5	4%
Depreciation	1.6	1.6	3%
Amortisation	0.2	0.1	-50%
Underlying EBIT	8.3	8.8	6%
<i>EBIT/Sales %</i>	<i>8%</i>	<i>9%</i>	



- ▶ Improvement reported in sales and underlying EBIT
- ▶ Revenue growth in New Zealand and Europe more than offset declines in other markets
- ▶ New CEO appointed May 2014
- ▶ Profit improvement plan being framed currently
 - Addressing unprofitable segments and supply chain costs
- ▶ Major new product launches occurring in FY15 to generate growth

Automotive

\$ million	FY13	FY14	% Change
Sales	87.3	95.4	9%
EBITDA	28.5	30.9	8%
Depreciation	0.6	0.6	4%
Amortisation	0.0	0.0	
Underlying EBIT	27.9	30.3	8%
<i>EBIT/Sales %</i>	<i>32%</i>	<i>32%</i>	



- ▶ Continued strong financial performance
- ▶ Ryco and Wesfil growing market share
- ▶ Ryco launched new agricultural filters and revamped cabin air program
- ▶ Goss brand fuel pumps introduced to New Zealand market
- ▶ Wesfil continues to benefit from national footprint and service offer and new products
- ▶ FY15 improvement to come from further new product activity and organic growth

Oates

\$ million	FY13	FY14	% Change
Sales	65.7	67.0	2%
EBITDA	11.5	11.9	3%
Depreciation	0.6	0.7	8%
Amortisation	0.1	0.1	24%
Underlying EBIT	10.8	11.1	3%
<i>EBIT/Sales %</i>	<i>17%</i>	<i>17%</i>	



- ▶ Improvement in financial performance in FY14
- ▶ Sales improvement in hardware and commercial more than offset a decline in supermarkets
- ▶ Profit improvement plan in early stage of development
- ▶ Steady performance anticipated through FY15 with some contribution from new products

Lock Focus

\$ million	FY13	FY14	% Change
Sales	9.9	10.5	6%
EBITDA	1.6	1.5	-3%
Depreciation	0.7	0.6	-12%
Amortisation	0.0	0.0	
Underlying EBIT	0.8	0.9	4%
<i>EBIT/Sales %</i>	<i>8%</i>	<i>8%</i>	



- ▶ Sales to new market segments drove sales growth
- ▶ FY15 sales should benefit from commercialisation of new products for original equipment customers

Outlook

- ▶ Business conditions expected to remain largely unchanged over FY15
 - Currency effects predominantly hedged
 - Modest organic growth across most businesses expected
- ▶ Restructuring fully provided and activities to be completed
 - Dexion profit improvement expected
 - \$10 million annualised benefit across the group by FY16
- ▶ Profit improvement plans in place or being developed
 - Focus on supply chain, cost-to-serve, warranty and product rationalisation
 - Anticipate \$20 million of annualised benefit over next two years
- ▶ Innovation programs to deliver first breakthroughs in early FY16
 - First concepts undergoing feasibility and market testing
 - Breakthroughs include new products, new channels and new services

